Antimicrobial Stewardship · India

India is the
AMR capital
of the world.

Demed is closing the loop — inside your hospital.

Antibiotics are failing. AMR kills more Indians every year than COVID did in total — and PM Modi is now sounding the alarm. The fix doesn't need a new drug. It needs a better workflow.

See How It Works
10.4L
Deaths associated with AMR in India (2019 data, 2024 GRAM estimate). Directly attributable: ~2.1L. Associated: ~6.9L.
Lancet GRAM Project, Sep 2024 · Cited by PM Modi, Dec 2025
58,000
Newborns die from antibiotic-resistant sepsis in India every year
ICMR AMR Surveillance Network
56%+
Of India's AMR burden originates inside healthcare settings. K. pneumoniae resistance: 9% in 2008 → 60%+ by 2024
SAPCAR-G 2024 · ICMR AMRSN Annual Report
The Problem

The workflow gap
no one talks about.

India leads the world in antibiotic resistance. The dominant driver isn't community misuse — it's what happens inside hospital walls.

Giving a patient the wrong dose harms them — hospitals have entire systems to prevent that. We call it a medication error. Now imagine hundreds of thousands of sepsis patients on the wrong antibiotic for up to 48 unnecessary hours, every year, because a clinical pharmacist can't reach the doctor in time. That's the AMR workflow gap inside Indian hospitals. And it's entirely preventable.
Why Now

The window is
open right now.

Three forces converged in 2025 to make this the most important moment in Indian hospital history for antimicrobial stewardship.

⚖️
NABH just made AMS mandatory — January 2025
The National Accreditation Board for Hospitals & Healthcare Providers has made a formal Antimicrobial Stewardship Programme a mandatory requirement for accreditation from January 2025. Every accredited hospital in India must now have a functioning AMS programme — or lose accreditation. There is no digital-native Indian platform to help them comply. Until now.
43,000+
Private hospitals in India — all facing the NABH AMS mandate. Every accredited hospital needs a compliance solution now.
0
India-native AI AMS platforms exist today. The global alternatives (Sentri7, TheraDoc) have 12-month sales cycles and aren't built for Indian workflows.
6 weeks
Demed deployment time vs competitors' 12-month sales cycle. We can reach 50 hospitals before they notice India exists.
Evidence · In the News

The crisis is documented.

From PM Modi's Mann Ki Baat to The Lancet and Nature India — AMR has reached the highest levels of scientific and political attention.

The Solution

Lab result to
doctor approval.

Up to 48 hours → Under 5 minutes

Demed is an AI-powered AMS platform built for Indian hospital workflows — clinical pharmacist to physician in minutes, not days.

Step 01
🔬
Lab result arrives
E. coli sensitive to ceftriaxone. Patient on meropenem since Monday. Dashboard flags it automatically.
→
Step 02
🤖
AI analyses
Checks chart, allergies, eGFR, AWaRe classification. Clinical de-escalation recommendation at 94% confidence.
→
Step 03
💊
Clinical Pharmacist approves
Reviews, edits, approves in 30 seconds. "Clinical Pharmacist recommends" — not "AI says." Pushed to doctor instantly.
→
Step 04
📱
Doctor approves
Push notification. One tap. Face ID. NABH audit trail auto-generated. Order updated. Under 5 minutes total.
What the AI is doing
⚖️
AWaRe Classification
Scores every antibiotic — Access, Watch, Reserve. Always pushing toward safer, narrower-spectrum agents.
🫘
Renal Dose Check
eGFR auto-checked for every recommendation. Prevents nephrotoxic dosing errors in ICU settings.
🧬
ESBL Rules Enforced
Never de-escalates to cephalosporins in ESBL-positive cases, even if the lab shows sensitivity.
📍
Local Antibiogram
Calibrated to your hospital's own resistance data. Your bugs, your patterns — gets smarter every case.
₹42K
Drug cost saved per patient/day
−60%
C. diff infection risk reduction
Auto
NABH audit trail, every action
⚙ Integration-ready
HL7 v2 · FHIR · EMR-agnostic. Works with basic HIS, connects to Epic & Cerner.
✓ NABH / JCI Compliance
Actor, timestamp, IP logged. One-click NABH PDF. DPDP-compliant India data residency.
📱 Web + Mobile
Clinical Pharmacist web dashboard. Doctor native mobile. Real push notifications. Biometric approval.
Published Research · Peer-Reviewed

The science already works.

Demed's core workflow is validated by a prospective 560-patient study — published Wolters Kluwer, January 2026.

"Impact of De-escalation Review Form as a Part of Antimicrobial Stewardship Program — A Prospective Observational Study"
560
Patients · 10-month prospective
+44%
De-escalation acceptance (p=0.0064)
51→68%
Overall acceptance rate
18→13%
Mortality reduction
What this proves: A structured de-escalation review form — exactly what Demed digitises with AI — increased de-escalation acceptance by 44% and reduced mortality by 5 percentage points. The bottleneck is workflow, not clinical knowledge.
J Clin Infect Dis Soc 2025;3:290–7 · Wolters Kluwer Medknow · DOI: 10.4103/CIDS.CIDS_61_24 · Continental Hospitals, Hyderabad
The Team

We didn't read about this.
We lived it.

Clinical insight meets product execution. Every credential is a reason we — and only we — are the right team to build this.

Chaitanya S.V.
Chaitanya S.V.
Co-founder & CEO · PharmD, AMS Researcher
Chaitanya is not studying the problem — she is the clinical pharmacist the product is built for. She lived the 48-hour delay as an AMS researcher and clinical pharmacist in Continental Hospitals Hyderabad's ICU, ran daily culture-guided de-escalation rounds, and then published the peer-reviewed research that forms Demed's scientific foundation.

Her 560-patient prospective study — published Wolters Kluwer, Jan 2026, under Dr. Vijay Yeldandi — is the bedrock of this product. She also brings inside knowledge of GCC healthcare through her experience as a pharmacist and store manager at Life Pharmacy UAE (DHA & DOH licensed).
PharmD · RGUHSAMS · ICU · ContinentalPublished Jan 2026DHA · DOH · India RPh
Vikash Suresh
Vikash Suresh
Co-founder & COO · AI Product, GTM
Vikash has done the hardest thing in startups — taken a product from zero to exit. He founded, built and exited Recorem, an AI/ML-enabled HR tech platform. He knows 0-to-1 product development, GTM, and team-building from first principles.

At Toptal, he leads product and project management consulting within talent operations — working directly with SMB and enterprise clients to understand their build needs and deploy the right teams. He built Demed's live production platform — AI integration, multi-device push notifications, biometric auth, NABH audit trail — in under 48 hours.
Founder · Exited RecoremAI ProductDirector of Product · ToptalCSPO · CSM
Partner With Us

Ready to close
the AMS loop?

We're partnering with hospitals for our first pilot cohort. Hospital leader, clinician, or technology expert — let's talk.